Inadequate glycemic control amongst patients with Type 2 diabetes mellitus (T2DM) indicates a major public health problem and a significant risk factor for the progression and complications caused by diabetes. Glycemic control is the main therapeutic objective for the prevention of organ damage and other complications arising from diabetes. This was a retrospective observational study of T2DM patients with complications, who were aged 40 years and older. The study was conducted retrospectively on medical records (in-patient and out-patient) obtained from a South Indian teaching hospital, Manipal, India. The patients included in the study had fasting blood sugar, postprandial blood sugar and HbA1c measured at least twice during follow-ups the previous year. Patients' HbA1c levels were categorized into good control ≤7% (≤53mmol/mol), and poor control >7% (>53mmol/mol), and patients' characteristics were analyzed. A total of 657 patients were included in the study. The mean age was 59.67 (SD = 9.617) years, with 152 (23.1%) females and 505 (76.9%) males, and 514 (78.2%) patients had poor glycemic control. Most of the patients were on insulin mono-therapy [n = 271 (42.1%)], about a third of the patients were on combination therapy that included an oral hypoglycemic agent and insulin [n = 236 (36.6%)]. Patients with a history of more than 10 years of diabetes [n = 293 (44.6%)], had a family history of diabetes [n = 256 (39%)] and obesity [n = 95 (14.5%)], all had poor glycemic control. This present study indicated a significant association of gender (female), age, high-density lipoprotein level, duration of diabetes and type of medication, with poor glycemic control in T2DM patients that had secondary medical complications.
The aim of this study was to investigate the prevalence of ESBL and MBL encoding genes among A. baumannii isolates. In this cross sectional study, 100 A. baumannii strains were isolated from ICU wards of 3 educational hospitals of Hamadan City, Iran in 2011. Phenotypic identification of the production of ESBLs and MBLs has been carried out by using E-test and DDST methods, respectively. PCR technique was used for amplification of the ESBL and MBL encoding genes, namely: CTX-M, SHV, TEM, OXA-51, VIM-Family, IMP-Family, SPM-1, SIM-1, and GIM-1. Eighty seven (87%), 95 (95%), 98 (98%) and 95 (95%) out of 100 A. baumannii isolates were resistant to imipenem, meropenem, ceftazidime and cefotaxime, respectively. Also, 99% and 7% of the isolates were MBLs and ESBLs produced phenotypically. Thirty (30%), 20 (20%) and 58 (58%) out of 100 A. baumannii isolates have been confirmed to harbor the bla VIM-family, TEM and SHV genes, respectively. Our results show no significant relationship between the detected gens with production of MBLs and ESBLs in spite of high prevalence of MBL encoding and drug resistant A. baumannii. Probably some other genes rather than what we studied are involved in phenotypic production of MBLs and ESBLs and subsequent drug resistance in Hamadan area, Iran.
27 August 2013 in Food Additives & Contaminants: Part B
Aflatoxin M1 (AFM1) contamination is evaluated in 120 samples of raw milk from cow and buffalo (60 each), collected randomly in the Shush (southwest Iran). Enzyme-linked immunoabsorbent assay (ELISA) was applied to analyse AFM1 in the samples. AFM1 was detected in 44 (69%) raw cow milk samples with a mean of 55 ng/l at a range of 3.6-419 ng/l) and in 46 (79%) raw buffalo milk samples with a mean of 116 ng/l at a range of 13-423 ng/l. In all samples, the AFM1 concentration was lower than the Iranian national standard and FDA limit of 500 ng/l. According to the European Union and Codex Alimentarius Commission, 18 (28%) and 32 (52%) of cow and buffalo raw milk samples are above the 50 ng/l limit, respectively. Results showed that AFM1 contamination of raw milk could pose a problem for public health, since all age groups, including infants and children, consume this product.
Due to their nutritional value, dairy products are popular in Iran. However, several reports have demonstrated that aflatoxin M1 (AFM1) contamination of milk and dairy products are challenging for human health, especially children. This manuscript is a review of some reports about the occurrence of AFM1 in Iranian dairy products published between 2005 and 2013. The studies analyzed a total of 11 107 dairy products samples composed of raw milk, UHT milk, pasteurized milk, traditional cheese, UF cheese, cream cheese, feta cheese, white cheese, butter, ice cream, infant milk products, Doogh and yoghurt. Current AFM1 analysis was conducted by various methods including thin layer chromatography, high-performance liquid chromatography and enzyme-linked immunoassays; but the ELISA method is mostly used in Iran because of its rapidity, simplicity and cheapness. The mean contamination level of AFM1 in autumn and winter samples was significantly higher than spring and summer. According to European Commission limit, i.e. 50 ng/kg, the reported range of contamination in analyzed dairy products exceeded the limit was in the range of 0–100%.